ATE290089T1 - METHOD FOR ENHANCING THE BIOLOGICAL ACTIVITY OF LIGANDS - Google Patents

METHOD FOR ENHANCING THE BIOLOGICAL ACTIVITY OF LIGANDS

Info

Publication number
ATE290089T1
ATE290089T1 AT99968956T AT99968956T ATE290089T1 AT E290089 T1 ATE290089 T1 AT E290089T1 AT 99968956 T AT99968956 T AT 99968956T AT 99968956 T AT99968956 T AT 99968956T AT E290089 T1 ATE290089 T1 AT E290089T1
Authority
AT
Austria
Prior art keywords
polypeptide ligands
fusion polypeptide
ligands
enhancing
biological activity
Prior art date
Application number
AT99968956T
Other languages
German (de)
Inventor
Samuel J Davis
Nicholas W Gale
George D Yancopoulos
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE290089T1 publication Critical patent/ATE290089T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel fusion polypeptide ligands that bind Eph family receptors or the Tie-2 receptor are identified, and methods for making the fusion polypeptide ligands in biologically active form are described. Nucleic acids encoding these novel fusion polypeptide ligands enable production of the fusion polypeptide ligands. The method of making the nucleic acids and the fusion polypeptide ligands is broadly applicable to the production of polypeptide ligands in general, resulting in improved affinity and/or increased activity of the ligand when compared to its native form.
AT99968956T 1998-12-23 1999-12-23 METHOD FOR ENHANCING THE BIOLOGICAL ACTIVITY OF LIGANDS ATE290089T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11338798P 1998-12-23 1998-12-23
PCT/US1999/030900 WO2000037642A1 (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Publications (1)

Publication Number Publication Date
ATE290089T1 true ATE290089T1 (en) 2005-03-15

Family

ID=22349103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968956T ATE290089T1 (en) 1998-12-23 1999-12-23 METHOD FOR ENHANCING THE BIOLOGICAL ACTIVITY OF LIGANDS

Country Status (12)

Country Link
US (1) US7008781B1 (en)
EP (1) EP1141294B1 (en)
JP (1) JP4493854B2 (en)
AT (1) ATE290089T1 (en)
AU (1) AU776393B2 (en)
CA (1) CA2354846A1 (en)
DE (1) DE69924009T2 (en)
HK (1) HK1040093B (en)
IL (1) IL143558A0 (en)
NZ (1) NZ512326A (en)
PL (1) PL199645B1 (en)
WO (1) WO2000037642A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901428D0 (en) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
AU2337801A (en) * 1999-12-23 2001-07-09 An-Go-Gen Inc. Angiopoietin analogs
AU2001280060A1 (en) * 2000-08-08 2002-02-18 M.G.V.S. Ltd. Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7052695B2 (en) 2001-10-25 2006-05-30 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of treating hypertension
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US8298532B2 (en) * 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US20100150834A1 (en) * 2006-09-15 2010-06-17 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
PT2076290T (en) 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
DK2983695T3 (en) 2013-04-11 2019-09-02 Sunnybrook Res Inst PROCEDURES, APPLICATIONS AND COMPOSITIONS OF TIE2 AGONISTS
PL3062811T3 (en) 2013-11-01 2019-10-31 Regeneron Pharma Angiopoietin-based interventions for treating cerebral malaria
EP3370757B1 (en) 2015-11-06 2021-04-14 Regeneron Pharmaceuticals, Inc. Angiopoietins for use in promoting blood coagulation and in the treatment of blood coagulation disorders
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003569A1 (en) * 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2149333C (en) 1992-11-13 2002-01-22 Timothy D. Bartley Eck receptor ligands
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
IL113252A0 (en) * 1994-04-04 1995-07-31 Regeneration Pharmaceuticals I Eph receptors binding ligands
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
WO1996031598A1 (en) 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
JPH11514238A (en) 1995-10-25 1999-12-07 リジェネロン ファーマシューティカルズ，インコーポレイテッド Biologically active EPH family ligands
DE69635899T2 (en) * 1995-11-17 2006-11-23 Asahi Kasei Kabushiki Kaisha POLYPEPTIDE THAT SUPPRESSING DIFFERENTIATION
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
WO1997023639A1 (en) * 1995-12-22 1997-07-03 Toray Industries, Inc. Process for producing biologically active fused proteins
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
JP2000513932A (en) 1996-06-19 2000-10-24 リジェネロン ファーマシューティカルズ，インコーポレイテッド TIE-2 receptor ligands (TIE ligand-3; TIE ligand-4) and uses thereof
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Also Published As

Publication number Publication date
HK1040093A1 (en) 2002-05-24
DE69924009T2 (en) 2006-04-13
WO2000037642A1 (en) 2000-06-29
JP4493854B2 (en) 2010-06-30
NZ512326A (en) 2003-11-28
WO2000037642A9 (en) 2000-11-02
IL143558A0 (en) 2002-04-21
AU776393B2 (en) 2004-09-09
HK1040093B (en) 2005-05-06
DE69924009D1 (en) 2005-04-07
US7008781B1 (en) 2006-03-07
CA2354846A1 (en) 2000-06-29
EP1141294B1 (en) 2005-03-02
EP1141294A1 (en) 2001-10-10
PL199645B1 (en) 2008-10-31
PL349158A1 (en) 2002-07-01
AU2714700A (en) 2000-07-12
JP2003506008A (en) 2003-02-18

Similar Documents

Publication Publication Date Title
ATE290089T1 (en) METHOD FOR ENHANCING THE BIOLOGICAL ACTIVITY OF LIGANDS
CY1108175T1 (en) DcR3 polypeptide, TNFR homologue
ATE255420T1 (en) USE OF TUMOR CELLS IN COMBINATION WITH INTACT ANTIBODIES FOR IMMUNIZATION
ATE212059T1 (en) METHODS FOR IDENTIFYING HETEROFUNCTIONAL FUSION PROTEINS
DE69534588D1 (en) PROTOCADHERINE PROTEINS AND USES THEREOF
IL130403A (en) Oil bodies and associated proteins as affinity matrices
ATE135371T1 (en) PROTEIN ASSOCIATED WITH ACUTE PANCREATITIS, AGENTS FOR DIAGNOSING ACUTE PANCREATITIS
ATE522609T1 (en) NEUROTROPHIC FACTORS
ATE172493T1 (en) RECOMBINANT DNA AGENT AND METHODS
FI104180B1 (en) Method for Preparation of a Polypeptide, Antibody and Composition for the Management of IL-4 Mediated Conditions
DE69941701D1 (en) MUTANTS OF FLT3-L AND ITS USES
ATE328101T1 (en) STRUCTURAL PROTEIN OF ADENO-ASSOCIATED VIRUS WITH ALTERED CHROMATOGRAPHIC PROPERTIES
EA200300708A1 (en) METHODS OF OBTAINING MULTIMENSIVE PROTEINS AND RELATED COMPOSITIONS
DE69534551D1 (en) NEW METHOD FOR DETERMINING AND EVALUATING BIOLOGICALLY ACTIVE MOLECULES
RU2007142191A (en) HGF BETA CHAIN OPTIONS
SE8801701D0 (en) PRODUCTION TECHNOLOGY BASED ON ENZYMIC METHOD
DE69737651D1 (en) CORTISTATIN: NEUROPEPTIDE, COMPOSITIONS AND METHODS
ATE525390T1 (en) USE OF RESISTANT SPECIFIC ANTIBODIES IN THE TREATMENT OF DIABETES
ES2192199T3 (en) LIGANDOS OF THE EPH BIOLOGICALLY ACTIVE FAMILY.
Sapp et al. Characterization of a 48‐kDa nucleic‐acid‐binding fragment of nucleolin
DK1009817T3 (en) RTD receptor
ATE348171T1 (en) PROTEINS WITH LECITHIN-CHOLESTEROL ACETYLTRANSFERASE-LIKE ACTIVITY, THEIR PRODUCTION AND USE
DK0939769T3 (en) The vertebrate Smoothened proteins
DE60029748D1 (en) BIOLOGICAL CONTROL OF NEMATODES
DE3782549D1 (en) NEW POLYPEPTIDES, THEIR PRODUCTION AND THEIR USE.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141294

Country of ref document: EP